multiple myeloma
NICE recommends Celgene’s Revlimid in treatment-naive multiple myeloma
May 20, 2019Sales and Marketing Celgene, NICE, Revlimid, UK, multiple myeloma
Celgene’s Revlimid (lenalidomide) has been recommended by NICE for use on the NHS in England and Wales in combination with …
FDA puts multiple myeloma trial on hold after patient deaths
March 20, 2019Research and Development AbbVie, FDA, Roche, clinical trials, multiple myeloma
The FDA has placed a partial clinical hold on studies of multiple myeloma treatment Venclexta/Venclyxto (venetoclax) following a number of …
Sanofi’s Icaria combo extends progression-free survival in multiple myeloma at Phase 3
February 6, 2019Research and Development Icaria, Sanofi, multiple myeloma, pharma
Sanofi has continued to make progress in the development of Icaria (isatuximab), with the company announcing that the therapy met …
Darzalex “significantly reduces” disease progression and death in multiple myeloma at ASH 2018
December 5, 2018Research and Development ASH 2018, Janssen, darzalex, multiple myeloma, pharma
Janssen has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to unveil new Phase 3 …
FDA approves BMS’ multiple myeloma combo after it doubles progression-free survival
November 7, 2018Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Empliciti, FDA, US, multiple myeloma, pharma
The FDA has seen fit to approve Bristol-Myers Squibb’s Empliciti (elotuzumab) intravenous injection in combination with pomalidomide and dexamethasone for …
Europe approves Janssen’s Darzalex in frontline multiple myeloma
September 4, 2018Manufacturing and Production, Research and Development, Sales and Marketing EU, Europe, J&J, JJ, Janssen, darzalex, multiple myeloma, pharma
Janssen has revealed that its CD38-targeting biologic drug Darzalex (daratumumab) has received approval from the European Commission, authorising its use …
Takeda’s Ninlaro clears Phase 3 endpoint as maintenance therapy in multiple myeloma
July 12, 2018Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma
After making headlines with its mammoth deal to acquire Shire earlier this year, Takeda has emerged with new Phase 3 …
J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex
May 29, 2018Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq
Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …
Genmab and Janssen’s Darzalex combo scores FDA approval in multiple myeloma
May 8, 2018Manufacturing and Production, Sales and Marketing FDA, Genmab, Janssen, US, darzalex, multiple myeloma, pharma
Genmab and Janssen have revealed that their combination of Darzalex (daratumumab) with bortezomib (Velcade), melphalan, and prednisone (VMP) has received …
Top Ten most popular articles on Pharmafile.com this week
February 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Alzheimer's, AstraZeneca, Eylea, FDA, Microsoft, Regeneron, Shire, Tremfya, eurordis, multiple myeloma, rare disease
It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …
Read Pharmafocus January/February 2018 edition online now!
January 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Ablynx, Alex Azr, Celgene, Pharmafocus, Sanofi, UK, artificial intelligence, bioverativ, brexit, juno therapeutics, multiple myeloma, serialisation
With the holiday period a distant memory by now, Pharmafocus is back with its January/febraury edition. It’s hard to imagine …
FDA clears Amgen’s bone drug for multiple myeloma
January 8, 2018Sales and Marketing Amgen, Cancer, Xgeva, multiple myeloma, pharma
Amgen has announced that the FDA has approved the indication expansion of its drug Xgeva (denosumab) to include the treatment …
J&J’s Darzalex cuts risk of disease progression and death by 50%, new study shows
December 13, 2017Research and Development Genmab, J&J, JJ, Janssen, Johnson & Johnson, darzalex, multiple myeloma, pharma
Johnson and Johnson has revealed data which demonstrates that Darzalex (daratumumab), when combined with a regimen of bortezomib, melphalan and …
Different gene mutations in multiple myeloma depending on ancestry
November 24, 2017Medical Communications, Research and Development biotech, drugs, multiple myeloma, pharma, pharmaceutical
Researchers, based in the US, have conducted a large-scale collection of publicly available data and found that significant differences can …
GSK’s experimental multiple myeloma scores Breakthrough designation with FDA
November 3, 2017Medical Communications, Research and Development, Sales and Marketing Cancer, FDA, GSK, GlaxoSmithKline, multiple myeloma, pharma
GlaxoSmithKline is celebrating the FDA’s decision to award its experimental therapy GSK2857916 with Breakthrough Therapy Designation as a monotherapy in …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
Coriolis Pharma appoints Teun van der Heide as CEO
The evidence bar impacting UK medical cannabis access
